Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborators: Forest Laboratories; MS-Hub Seattle; University of Southern California; University of Texas Southwestern Medical Center
• Treatments: Memantine

Criteria

Inclusion Criteria:

1. A diagnosis of multiple sclerosis as defined by the McDonald criteria. Patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS are eligible.

2. Age between 18 and 65 years.

3. Demonstrated cognitive dysfunction at screening defined as a score worse than 1.0 standard deviations below the mean on the PASAT or the CVLT-II.

Exclusion Criteria:

1. A history of major depression, psychosis, or a score > 19 on the Beck's Depression Inventory.

2. Corrected binocular visual acuity worse than 20/50; any impairment of binocular color vision.

3. Patients that do not speak English as a primary language (fluency may impact performance).

4. A clinically significant MS exacerbation within 30 days of the screening

5. Pregnancy

6. Renal insufficiency.

7. History of seizures.

8. Patients using acetazolamide (Diamox, Ak-sol, Storzolamide), dichlorphenamide (Daranide), methazolamide (Neptazane) or topiramate (Topamax), dextromethorphan (Robitussin DM and other cold remedies), or amantadine (Symmetrel).

9. Use of medical marijuana in the prior six months.

10. History of alcohol abuse or illicit drug use in the prior six months.